发明名称 |
METHODS AND COMPOSITIONS FOR INCREASING ALPHA-L-IDURONIDASE ACTIVITY IN THE CNS |
摘要 |
Provided herein are methods and compositions for treating a subject suffering from a deficiency in α-L-Iduronidase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an α-L-Iduronidase. A therapeutically effective systemic dose is based on the specific CNS uptake characteristics of human insulin receptor antibody-α-L-Iduronidase fusion antibodies as described herein. |
申请公布号 |
US2017114152(A1) |
申请公布日期 |
2017.04.27 |
申请号 |
US201715397649 |
申请日期 |
2017.01.03 |
申请人 |
Armagen, Inc. |
发明人 |
Pardridge William M.;Boado Ruben J. |
分类号 |
C07K19/00;C12N9/00;C12N9/24;C07K16/28 |
主分类号 |
C07K19/00 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method for treating an α-L-iduronidase deficiency in the central nervous system of a subject in need thereof, comprising systemically administering to the subject a therapeutically effective dose of a fusion antibody having α-L-iduronidase activity, wherein:
(i) at least about 0.5% of the therapeutically effective dose is delivered to the brain; (ii) the fusion antibody: comprises: (a) a fusion protein containing the amino acid sequence of an immunoglobulin heavy chain and an α-L-iduronidase, and (b) an immunoglobulin light chain; (iii) the fusion antibody binds to an extracellular domain of the human insulin receptor; and catalyzes hydrolysis of unsulfated alpha-L-iduronosidic linkages in dermatan sulfate; and (iv) the amino acid sequence of the α-L-iduronidase is covalently linked to the carboxy terminus of the amino acid sequence of the immunoglobulin heavy chain. |
地址 |
Calabasas CA US |